vs
Side-by-side financial comparison of BioNTech SE (BNTX) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $872.7M, roughly 1.7× Primerica, Inc.). Primerica, Inc. runs the higher net margin — 21.8% vs -1.9%, a 23.7% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
BNTX vs PRI — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $872.7M |
| Net Profit | $-28.7M | $190.1M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | — |
| Net Margin | -1.9% | 21.8% |
| Revenue YoY | — | 8.4% |
| Net Profit YoY | — | 12.4% |
| EPS (diluted) | — | $5.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $872.7M | ||
| Q4 25 | — | $853.7M | ||
| Q3 25 | $1.5B | $839.9M | ||
| Q2 25 | $260.8M | $793.3M | ||
| Q1 25 | — | $804.8M | ||
| Q4 24 | — | $768.8M | ||
| Q3 24 | $1.2B | $774.1M | ||
| Q2 24 | — | $803.4M |
| Q1 26 | — | $190.1M | ||
| Q4 25 | — | $197.0M | ||
| Q3 25 | $-28.7M | $206.8M | ||
| Q2 25 | $-386.6M | $178.3M | ||
| Q1 25 | — | $169.1M | ||
| Q4 24 | — | $167.1M | ||
| Q3 24 | $198.1M | $164.4M | ||
| Q2 24 | — | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 98.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 28.9% | ||
| Q3 25 | -3.1% | 32.3% | ||
| Q2 25 | -192.1% | 29.6% | ||
| Q1 25 | — | 27.5% | ||
| Q4 24 | — | 64.7% | ||
| Q3 24 | 0.8% | 32.9% | ||
| Q2 24 | — | 1.0% |
| Q1 26 | — | 21.8% | ||
| Q4 25 | — | 23.1% | ||
| Q3 25 | -1.9% | 24.6% | ||
| Q2 25 | -148.2% | 22.5% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | 15.9% | 21.2% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | $5.97 | ||
| Q4 25 | — | $6.11 | ||
| Q3 25 | — | $6.35 | ||
| Q2 25 | — | $5.40 | ||
| Q1 25 | — | $5.05 | ||
| Q4 24 | — | $4.92 | ||
| Q3 24 | — | $4.83 | ||
| Q2 24 | — | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $645.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $2.5B |
| Total Assets | — | $14.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $645.8M | ||
| Q4 25 | — | $756.2M | ||
| Q3 25 | — | $644.9M | ||
| Q2 25 | — | $621.2M | ||
| Q1 25 | — | $625.1M | ||
| Q4 24 | — | $687.8M | ||
| Q3 24 | — | $550.1M | ||
| Q2 24 | — | $627.3M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | $2.4B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.1B |
| Q1 26 | — | $14.7B | ||
| Q4 25 | — | $15.0B | ||
| Q3 25 | — | $14.8B | ||
| Q2 25 | — | $14.8B | ||
| Q1 25 | — | $14.6B | ||
| Q4 24 | — | $14.6B | ||
| Q3 24 | — | $14.8B | ||
| Q2 24 | — | $14.6B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
